AstraZeneca Pharma India Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
ASTRAZEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
AstraZeneca Pharma India reported strong Q1 FY26 results with revenue from operations rising 36% year-on-year to Rs 5,263.1 million (vs Rs 3,875.2 million in Q1 FY25). Profit before exceptional items and tax jumped to Rs 750.6 million from Rs 424.0 million, while profit after tax turned positive at Rs 558.3 million versus a Rs 117.9 million loss in the same quarter last year. EPS for the quarter was Rs 22.33 compared to a loss of Rs 4.72 in Q1 FY25. Oncology led growth at Rs 3,702.7 million (+55% YoY), while Biopharmaceuticals saw a slight dip and Rare Disease remained small. The company has ceased operations at its Bangalore manufacturing site and begun decommissioning, with a plan to sell the facility.
Strong top-line growth and a return to profitability signal healthy business momentum, likely to be viewed positively by investors. However, the manufacturing site shutdown and ongoing restructuring costs are long-term strategic transitions rather than immediate concerns.